Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial.
Ontology highlight
ABSTRACT: The literature on pharmacogenomics as a tool to support antidepressant precision is burgeoning. Recently, a more active role has been argued for pharmacists in pharmacogenomic testing, with both pharmacists and family physicians perceiving pharmacist-led testing as a valuable method by which to scale this innovation for depression treatment. In this prospective, single-blind randomized controlled design, we evaluated the impact of pharmacogenomics guided versus standard antidepressant treatment of depression and anxiety, implemented in three large community pharmacies. Participants were 213 outpatients diagnosed with major depressive disorder and/or generalized anxiety disorder, randomized to receive pharmacogenomics guided (n = 105) or standard antidepressant treatment (n = 108); particip
SUBMITTER: Papastergiou J
PROVIDER: S-EPMC8301569 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA